• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Pharma industry news

Merck logo

Merck acquires OncoEthix, a privately held oncology company developing novel BET inhibitors for hematological and solid cancers

Posted on: 19 December 2014 | Source: Merck

Acquisition expands Merck’s oncology portfolio with novel oral BET inhibitor, OTX015...

Roche logo

Roche provides update on Phase III MARIANNE study in people with previously untreated advanced HER2-positive breast cancer

Posted on: 19 December 2014 | Source: Roche

Roche announced top-line results of the Phase III MARIANNE study...

Pfizer logo

Pfizer reports top-line results from a Phase 3 study evaluating pregabalin controlled-release formulation as a treatment for patients with postherpetic neuralgia

Posted on: 19 December 2014 | Source: Pfizer

Pfizer Inc. announced top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia...

Eli Lilly logo

Lilly’s CYRAMZA(R) (ramucirumab) receives third FDA approval

Posted on: 17 December 2014 | Source: Eli Lilly and Company

Eli Lilly and Company has received its third U.S. Food and Drug Administration (FDA) approval for CYRAMZA(R) (ramucirumab)...

GlobalData

Top 30 pharma companies spent $112 billion on research and development in 2013, says GlobalData

Posted on: 17 December 2014 | Source: GlobalData

The world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year, according to research and consulting firm GlobalData...

Pills

Selvita has raised PLN 27.3 MM on its way to the main market of the Warsaw Stock Exchange

Posted on: 17 December 2014 | Source: Selvita

Selvita, Poland-based integrated drug discovery partner for the pharmaceutical and biotechnology industry, has successfully completed its Initial Public Offering...

Boehringer Ingelheim logo

First trial of a novel oral anticoagulant starts in prevention of recurrent stroke due to a blood clot of undetermined source

Posted on: 16 December 2014 | Source: Boehringer Ingelheim

Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embolic Stroke of Undetermined Source, also called ESUS...

Refcode ZOYBIA

Cambridge structural database reaches 750,000 entry milestone

Posted on: 16 December 2014 | Source: The Cambridge Crystallographic Data Centre

Essential resource to scientists around the world reaches historic record...

Abbott logo

Abbott commences tender Offer and Consent Solicitation for CFR International SpA 5.125% Senior Notes due 2022

Posted on: 16 December 2014 | Source: Abbott

Abbott announced that its wholly-owned subsidiary, Abbott Laboratories (Chile) Holdco (Dos) SpA, a Chilean corporation ("ALH"), has commenced a tender offer (the "U.S. Notes Offer"), in which it is offering to purchase for cash any and all of the outstanding $300 million aggregate principal amount of 5.125% Senior Notes due 2022 (the "Notes") issued by CFR International SpA...

RMM Webinar Featured Image

Pharma Webinar: Practical Application of RMM in Pharmaceutical Manufacturing

Posted on: 15 December 2014 | Source: Scott Sutton Ph.D. - President of Pharmaceutical Microbiology Forum & Owner of The Microbiology Network & Dr. Yongqiang Zhang - Senior Scientist at BD Diagnostics

Discussion on how a rapid method can provide a solution to a common microbiological testing problem for pharmaceutical manufacturers – process water microbiology testing.

USAID

Orange and USAID join forces to boost mHealth innovations across Africa

Posted on: 15 December 2014 | Source: Orange

The U.S. Agency for International Development and global telecommunications operator Orange announced a new alliance to develop innovations in mobile health (mHealth) at the Global mHealth Forum in Washington, DC...

MSD Logo

UK patients with moderately to severely active ulcerative colitis gain access to a range of biologic therapies on the NHS

Posted on: 15 December 2014 | Source: MSD

NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...